Intel shares rise as Elon Musk touts potential Tesla chipmaking deal
Investing.com - Bernstein SocGen Group has reiterated an Outperform rating on Boston Scientific (NYSE:BSX) with a price target of $130.00, citing the company’s strong long-range plan for 2026-2028. The medical device maker, currently valued at $144.66 billion, maintains a strong "GREAT" financial health score according to InvestingPro data, with analysts maintaining a Strong Buy consensus.
The medical device maker expects to deliver organic sales compound annual growth rate (CAGR) of more than 10%, compared to its previous long-range plan of 8%-10%, according to Bernstein’s analysis of Boston Scientific’s investor day.
Boston Scientific also projects 50 basis points of annual adjusted operating margin expansion, 70%-80% free cash flow conversion, and leveraged double-digit earnings per share growth, all aligning with investor expectations.
Bernstein expressed "refreshed conviction" in its positive outlook on the stock, describing Boston Scientific as a "great stock story" with a reasonable valuation at less than 30 times next twelve months earnings per share.
The research firm believes Wall Street estimates remain conservative, noting that Boston Scientific’s organic growth is likely to remain well above 10% "for some time" while leveraged earnings per share growth continues.
In other recent news, Boston Scientific has been the focus of multiple analyst reports following its 2025 Investor Conference. The company reaffirmed its fiscal year 2025 organic sales growth forecast of 14-15% and maintained its long-term growth projection of at least 10%. Boston Scientific also set ambitious goals for adjusted operating margin expansion and double-digit adjusted EPS growth. Analysts responded positively, with Oppenheimer reiterating an Outperform rating and setting a price target of $125.00. Truist Securities raised its price target to $129.00, citing the company’s robust long-term plan for 2026-2028, which includes over 10% organic revenue growth and significant margin expansion. Canaccord Genuity and BTIG also increased their price targets to $132.00, highlighting Boston Scientific’s growth strategy and financial targets for the coming years. RBC Capital reiterated its Outperform rating and $125.00 price target, showing continued confidence in the company’s outlook. These developments underscore the positive sentiment among analysts regarding Boston Scientific’s future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.